For lab managers, the choice between single-use and stainless steel bioprocessing infrastructure is fundamentally a capital, operational, and strategic question. Both approaches can produce compliant, high-quality biologics; the decision turns on development stage, program mix, budget structure, and long-term scalability plans. Getting it wrong means either overcapitalizing a facility that needs flexibility, or underinvesting in infrastructure a commercial program will outgrow.

Quick Take

• Single-use systems eliminate cleaning validation and reduce changeover time, but carry ongoing consumables cost and supply chain risk that stainless steel does not
• Stainless steel infrastructure has lower lifetime operating cost at high, sustained utilization, but requires significant upfront capital and cleaning validation burden
• The facility's development stage is the most important contextual variable: clinical-stage programs often benefit from single-use; commercial-scale, single-product facilities often benefit from stainless
• Hybrid infrastructure, combining single-use upstream with stainless downstream (or vice versa), is increasingly common and often the most practical answer
• The single-use vs. stainless decision should be made alongside the lease-versus-buy analysis and the facility design plan, not independently

Single-use vs. stainless steel: why this is a capital decision, not an engineering one

The single-use vs. stainless question is typically framed as an engineering problem: which system produces better mixing dynamics, achieves the required oxygen transfer rate, or integrates most cleanly with the downstream train? Those are real considerations, but they are not where most lab managers make costly mistakes.

The costly mistakes happen at the capital planning level. A facility that installs stainless steel bioreactors for a Phase II program that subsequently fails has capitalized equipment it cannot easily redeploy or sell. A facility that commits to single-use at commercial scale for a high-volume product discovers that consumables spend erodes margins in ways that stainless infrastructure would not.

These are financial and strategic errors, not engineering ones. As the bioprocessing lab operations guide makes clear, the infrastructure decision is inseparable from the facility's budget cycle, program pipeline, and organizational risk tolerance.

This framework approaches the single-use vs. stainless steel bioprocessing decision from the operational and financial perspective where lab managers have the most influence, and where the most consequential choices are made.

CapEx vs. OpEx: how single-use and stainless steel distribute costs differently

The most fundamental difference between single-use and stainless steel bioprocessing infrastructure is how costs are distributed over time.

Stainless steel is a capital-intensive upfront investment. A GMP stainless steel bioreactor system at commercial scale, including the vessel, associated piping, CIP (clean-in-place) skid, SIP (steam-in-place) system, instrumentation, and installation, can represent $2 million to $10 million or more in capital expenditure (CapEx), depending on scale and vessel volume.

That cost is capitalized on the balance sheet and depreciated over 15 to 20 years for fixed stainless infrastructure. The ongoing operating expenditure (OpEx) is relatively low: utilities, maintenance, calibration, and periodic revalidation.

Advanced Lab Management Certificate

The Advanced Lab Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

Single-use systems invert this structure. The bioreactor bag, tubing sets, filters, and connectors are disposable consumables, OpEx rather than CapEx. The capital cost of a single-use bioreactor platform is substantially lower than an equivalent stainless system, but consumables spend accumulates over time.

At high utilization rates, the total cost of single-use consumables over a five-year horizon can exceed the capital cost of an equivalent stainless installation. At low utilization rates, single-use wins on total cost because consumables spend scales directly with production volume.

The leasing vs. buying framework applies directly here: the utilization rate threshold that determines whether CapEx or OpEx structures produce lower total cost of ownership (TCO) is the same analytical question whether the comparison is lease-versus-buy or single-use versus stainless.

Cleaning validation burden: the hidden operational cost of stainless steel

Cleaning validation is the most underestimated operational burden in stainless steel bioprocessing, and it is the single strongest argument for single-use systems in multiproduct or rapidly changing development environments.

Interested in lab leadership?

Register for a FREE Lab Manager account to subscribe to our Lab Leadership Digest Newsletter.

Subscribe for Free

Every time a stainless steel bioreactor or downstream vessel processes a new product, cleaning validation must demonstrate that the previous product has been removed to below a predefined limit. That validation requires development of a cleaning procedure, analytical method validation for residue detection, worst-case bracketing studies, and ongoing monitoring. In a multiproduct facility running five or six programs through the same stainless steel equipment, the cleaning validation burden is multiplied accordingly.

Single-use systems eliminate this burden entirely. Each batch uses a new disposable fluid path, so there is nothing to clean and nothing to validate for carryover. For development-stage facilities, CDMOs, or any organization running multiple products through shared infrastructure, this is more than a convenience; it is a GMP risk reduction that translates directly to faster batch release, fewer deviation events, and lower quality assurance overhead.

The regulatory expectations and practical methodologies that stainless steel operators must satisfy are surveyed comprehensively by Voss and O'Brien (2020), covering the cleaning validation requirements that apply under ICH Q7.

The GMP compliance framework for bioprocessing operations makes clear that cleaning validation is not a one-time event. It is an ongoing program with annual reviews, revalidation triggers, and documentation obligations that persist for the life of the equipment.

Facility design and operational flexibility: what each infrastructure choice locks in

Beyond cost structure and cleaning validation, the single-use vs. stainless choice has profound implications for facility flexibility, both in the short term and over the life of the building.

Single-use infrastructure requires less fixed utility installation: no CIP system to design and qualify, no steam distribution network for SIP, and no floor drains engineered for cleaning chemical runoff. A room designed for single-use bioreactors can be reconfigured for a different scale or product with relatively modest capital investment.

This flexibility is valuable for facilities expecting their program mix to change, or designing for a pipeline of products at different development stages. The GMP facility design guide for bioprocessing labs covers the utility and zoning decisions that flow from the single-use vs. stainless choice, decisions that, once made in concrete and pipework, are expensive to reverse.

Stainless steel infrastructure is essentially permanent by contrast. A facility designed around 500L stainless bioreactors, a CIP skid, and a fixed purification train is optimized for exactly that configuration. Scaling up requires new equipment purchases, new utility connections, and new qualification studies.

Changing product mix requires cleaning validation for each transition. This rigidity is a liability for development programs but an asset for commercial manufacturing of a stable, high-volume product, where the infrastructure is precisely calibrated to production needs and predictability outweighs the cost of inflexibility.

Single-use supply chain risk: the structural vulnerability stainless steel avoids

The 2020–2021 global supply chain disruptions exposed a structural vulnerability in single-use bioprocessing that stainless steel facilities do not face: the entire production capability of a single-use facility depends on the availability of bags, tubing, connectors, and filters from a small number of qualified suppliers.

A stainless steel bioreactor, once installed and qualified, is available for production until it fails mechanically. A single-use facility that cannot source its next shipment of bioreactor bags cannot run, regardless of the state of its equipment. The supply chain resilience guide for single-use components addresses the qualification of backup suppliers and the management of supplier change notifications, but the underlying risk is structural: single-use facilities trade cleaning validation burden for supply chain dependency.

This does not make single-use a poor choice. It means that single-use facilities must actively manage supply chain risk as an operational discipline. Qualifying backup suppliers for critical components, maintaining strategic inventory of high-lead-time items, and building supply assurance clauses into vendor contracts are operational requirements for single-use facilities in a way they simply are not for stainless steel operations.

Hybrid bioprocessing infrastructure: capturing the advantages of both technologies

The most common infrastructure decision in new GMP bioprocessing facilities is not a binary choice between single-use and stainless steel; it is a hybrid configuration that uses each technology where it performs best.

The most prevalent hybrid model uses single-use systems for upstream bioprocessing (cell culture, seed train bioreactors) and stainless steel for downstream purification (chromatography columns, ultrafiltration skids, bulk storage tanks). Upstream benefits most from single-use because that is where product changeover happens most frequently, contamination risk is highest, and flexibility has the greatest operational value. Downstream purification of a single product in a commercial facility benefits from stainless steel's lower OpEx and the precision of a validated, fixed process.

The reverse hybrid (stainless upstream, single-use downstream) is less common but relevant for facilities that have existing stainless bioreactor capacity they are not ready to retire. Single-use filtration and chromatography formats have matured enough that downstream single-use is now a viable option for many commercial programs, and it can reduce the cleaning validation burden in the downstream train even when the upstream remains stainless.

Designing a hybrid facility requires careful thought about where the boundary between the two systems sits and how the interface between them is managed. The facility planning process, the equipment procurement strategy, and the vendor qualification process all need to account for the specific requirements of each technology at the interface.

Decision guide: when single-use wins and when stainless steel wins

Single-use is likely the better choice when:

• The facility runs multiple products through shared infrastructure and cleaning validation burden is high
• The program is in clinical development and specifications may change before commercial launch
• The facility is designed for flexibility: a CDMO or a multiproduct development suite
• Scale does not exceed approximately 2,000L, where single-use platforms perform reliably
• Capital preservation is a priority and consumables spend is preferable to CapEx commitment
• Speed to first batch is operationally critical and qualification timelines must be minimized

Stainless steel is likely the better choice when:

• The facility manufactures a single approved product at sustained commercial volume
• Scale exceeds the practical ceiling of single-use platforms
• The product run schedule is predictable and cleaning validation can be planned and maintained
• Long-term TCO is the primary financial metric and the utilization rate justifies CapEx
• Supply chain reliability is non-negotiable and dependence on consumable components is unacceptable

Single-use vs. stainless steel bioprocessing: infrastructure follows strategy

The single-use vs. stainless steel bioprocessing decision cannot be made well in isolation. It belongs in the context of the facility's development stage, program pipeline, budget structure, and ten-year operational plan. Facilities that choose single-use because it is new, or stainless because it is familiar, without working through the CapEx/OpEx tradeoff, the cleaning validation burden, the supply chain implications, and the flexibility requirements, are making a decade-long commitment on incomplete information.

The decision should be made alongside the facility design, the equipment procurement plan, and the leasing vs. buying analysis, all of which are addressed in the broader bioprocessing lab operations guide. Infrastructure follows strategy, and the lab manager who frames this as a capital and operational question, not just a technical one, is best positioned to get it right.

References

1. Voss, J.R., & O'Brien, R.W. (2020). Cleaning and validation of cleaning in biopharmaceutical processing: A survey. In Biotechnology. CRC Press. https://doi.org/10.1201/9781003055297-7
2. ICH Expert Working Group. (2000). ICH Q7: Good manufacturing practice guide for active pharmaceutical ingredients. International Council for Harmonisation. https://database.ich.org/sites/default/files/Q7%20Guideline.pdf
3. ICH Expert Working Group. (2008). ICH Q10: Pharmaceutical quality system. International Council for Harmonisation. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf

This content includes text that has been generated with the assistance of AI. For more information, view Lab Manager's AI use policy.